Pancreatic Cancer Research

ResearcherArmy Medical UniversityActive in the last 2 years

Heshui Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2268-7275; OpenAlex author ID A5009540913, A5015608630. Sources: ClinicalTrials.gov.

Their work

Papers
73 (first author 5, last author 21)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
128
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 5 papers · 2017: 5 papers · 2018: 2 papers · 2019: 5 papers · 2020: 8 papers · 2021: 10 papers · 2022: 13 papers · 2023: 7 papers · 2024: 2 papers, 1 trial · 2025: 5 papers · 2026: 4 papers

Papers 50 of 73

  1. Prognostic value of body composition on early recurrence and long-term survival of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-025-12028-8↗
  2. HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1α transcriptional activation in pancreatic cancer. Co-author DOI 10.1016/j.molcel.2026.06.022↗
  3. PRMT1-Mediated Arginine Methylation Redirects SMAD4 Signaling to Promote Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0923↗
  4. E2F3 activates NF-κB signaling through TRIM26 mediated TAB1 ubiquitination in pancreatic cancer. Co-author DOI 10.7150/ijbs.127710↗
  5. Utility of a CAD model for estimation of vascular involvement and R0 resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/js9.0000000000003048↗
  6. Interpretable machine learning model for predicting early recurrence of pancreatic cancer: integrating intratumoral and peritumoral radiomics with body composi… Co-author DOI 10.1097/js9.0000000000003078↗
  7. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4↗
  8. [Emphasizing Principles of Surgical Oncology in Minimally Invasive Surgery for Pancreatic Cancer]. First author DOI 10.12182/20250760103↗
  9. BAP1 Represses Sequential Activation of IRAKs and NF-κB Signaling in Pancreatic Cancer. Co-author DOI 10.7150/ijbs.104977↗
  10. Ubiquitin ligase TRIM15 promotes the progression of pancreatic cancer via the upregulation of the IGF2BP2-TLR4 axis. Co-author DOI 10.1016/j.bbadis.2024.167183↗
  11. A clinical-radiomics nomogram based on dual-layer spectral detector CT to predict cancer stage in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40644-024-00700-z↗
  12. miR-222-3p-containing macrophage-derived extracellular vesicles confer gemcitabine resistance via TSC1-mediated mTOR/AKT/PI3K pathway in pancreatic cancer. First author DOI 10.1007/s10565-022-09736-y↗
  13. Transcriptome-based identification of tumor-reactive and bystander CD8+ T cell receptor clonotypes in human pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adh9562↗
  14. Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreati… Co-author DOI 10.1186/s13578-023-01155-8↗
  15. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. Co-author DOI 10.15252/embj.2023114558↗
  16. Correction for: Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pan… Last author DOI 10.18632/aging.205456↗
  17. Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancreatic Cancer. First author DOI 10.2214/ajr.22.28640↗
  18. Clinical-radiomics nomogram using contrast-enhanced CT to predict histological grade and survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1218128↗
  19. USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression. Co-author DOI 10.1002/1878-0261.13137↗
  20. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. Co-author DOI 10.1002/1878-0261.13149↗
  21. Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Im… Co-author DOI 10.1002/advs.202105240↗
  22. ITGA2 induces STING expression in pancreatic cancer by inducing DNMT1 degradation. Co-author DOI 10.1007/s13402-022-00731-3↗
  23. ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215855↗
  24. Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2 Pathway. Co-author DOI 10.1016/j.jcmgh.2022.07.008↗
  25. FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression. Co-author DOI 10.1038/s41388-021-02140-6↗
  26. HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-4362↗
  27. Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis. Co-author DOI 10.1186/s13046-022-02286-5↗
  28. A nomogram predicting overall survival for metastatic pancreatic cancer: SEER database analysis Co-author DOI 10.21203/rs.3.rs-1410601/v1↗
  29. Safety and Efficacy of Irreversible Electroporation in Locally Advanced Pancreatic Cancer: An Evaluation from a Surgeon's Perspective. Last author DOI 10.3390/cancers14225677↗
  30. CBX3 Regulated By YBX1 Promotes Smoking-induced Pancreatic Cancer Progression via Inhibiting SMURF2 Expression. Last author DOI 10.7150/ijbs.68995↗
  31. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Last author DOI 10.7150/thno.69444↗
  32. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Last author DOI 10.1016/j.bbadis.2021.166213↗
  33. SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Last author DOI 10.1016/j.canlet.2021.07.035↗
  34. TRIM47 accelerates aerobic glycolysis and tumor progression through regulating ubiquitination of FBP1 in pancreatic cancer. Co-author DOI 10.1016/j.phrs.2021.105429↗
  35. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer. Co-author DOI 10.1038/s41419-021-04118-4↗
  36. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Last author DOI 10.1038/s41420-021-00462-8↗
  37. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. Co-author DOI 10.1186/s10020-021-00300-8↗
  38. Circ-MBOAT2 knockdown represses tumor progression and glutamine catabolism by miR-433-3p/GOT1 axis in pancreatic cancer. Co-author DOI 10.1186/s13046-021-01894-x↗
  39. Long Non-coding RNA DLEU2L Targets miR-210-3p to Suppress Gemcitabine Resistance in Pancreatic Cancer Cells via BRCA2 Regulation. First author DOI 10.3389/fmolb.2021.645365↗
  40. Pancreatic Ductal Adenocarcinoma at CT: A Combined Nomogram Model to Preoperatively Predict Cancer Stage and Survival Outcome. Co-author DOI 10.3389/fonc.2021.594510↗
  41. Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. Co-author DOI 10.7150/jca.60340↗
  42. Long noncoding RNA ITGB2-AS1 promotes growth and metastasis through miR-4319/RAF1 axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcp.29471↗
  43. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Co-author DOI 10.1007/s13402-019-00476-6↗
  44. Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway. Co-author DOI 10.1016/j.omto.2020.03.006↗
  45. The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients. Last author DOI 10.1016/j.omto.2020.04.011↗
  46. The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis. Last author DOI 10.1186/s12935-020-01558-4↗
  47. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocar… Last author DOI 10.18632/aging.102931↗
  48. The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. Last author PMID 32064158↗
  49. Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. Last author PMID 33042621↗
  50. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.biocel.2019.01.011↗

Trials 1

  1. Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer Principal investigator NCT06361030↗

Closest collaborators

The 25 strongest of 128 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Jin · 24 shared papers, 2017–2023 · strength 3.31
  2. Dianyun Ren · 18 shared papers, 2020–2026 · strength 2.98
  3. Yingke Zhou · 12 shared papers, 2021–2026 · strength 2.20
  4. Shanmiao Gou · 12 shared papers, 2011–2026 · strength 1.93
  5. Jingyuan Zhao · 12 shared papers, 2018–2024 · strength 1.57
  6. Gengdu Qin · 8 shared papers, 2020–2026 · strength 1.43
  7. Tao Yin · 12 shared papers, 2011–2026 · strength 1.36
  8. Chunyou Wang · 16 shared papers, 2011–2023 · strength 1.33
  9. Zibo Meng · 9 shared papers, 2019–2023 · strength 1.19
  10. Feng Guo · 6 shared papers, 2021–2023 · strength 1.09
  11. Yan Sun · 7 shared papers, 2020–2024 · strength 1.05
  12. Taoyu Chen · 5 shared papers, 2022–2026 · strength 0.98
  13. Haixin Yu · 5 shared papers, 2022–2026 · strength 0.89
  14. Ping Han · 4 shared papers, 2023–2026 · strength 0.89
  15. Linxia Wu · 4 shared papers, 2023–2026 · strength 0.87
  16. Shihong Wu · 7 shared papers, 2019–2023 · strength 0.86
  17. Tao Peng · 5 shared papers, 2017–2023 · strength 0.77
  18. Hongkun Cai · 3 shared papers, 2022–2026 · strength 0.74
  19. Ping Fan · 9 shared papers, 2012–2021 · strength 0.74
  20. Chunyuan Cen · 4 shared papers, 2021–2025 · strength 0.73
  21. Chuansheng Zheng · 3 shared papers, 2024–2026 · strength 0.70
  22. Penglin Pan · 4 shared papers, 2022 · strength 0.61
  23. Jian Shen · 4 shared papers, 2021–2022 · strength 0.61
  24. Zhiqiang Liu · 6 shared papers, 2016–2021 · strength 0.61
  25. Hehe Li · 5 shared papers, 2017–2023 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.